This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Today, a brief rundown of news involving Novo Nordisk, Acelyrin and Intra-Cellular Therapies, as well as updates from Gilead Sciences and PhRMA that you might have missed.
The Food and Drug Administration has declared a two-and-a-half year shortage of Novo Nordisk’s metabolic drugs Ozempic for diabetes and Wegovy for obesity to be “resolved,” as of Friday. The decision follows the FDA’s declaration of an end to shortages for Eli Lilly’s competing drugs Mounjaro and Zepbound. The two companies have struggled with capacity as demand for the drugs has soared, particularly in obesity. To ensure supplies of compounded alternatives of the Novo drugs aren’t disrupted, the FDA said it won’t enforce any bans on those products until April 22 if manufactured at a state-licensed pharmacy or May 22 if they’re made at a federally authorized outsourcing facility. Shares in Hims & Hers Health, which has marketed compounded versions of the drugs, fell by more than 20% in Friday morning trading. — Jonathan Gardner
Concentra Biosciences, an entity controlled by investment firm Tang Capital Partners, has made an unsolicited bid for Acelyrin weeks after the company agreed to merge with fellow immune drug developer Alumis. Through the offer announced Thursday, Concentra intends to acquire Acelyrin for $3 per share in cash as well as the right to 80% of the proceeds if Concentra licenses or sells the company’s programs. Acelyrin stockholders would get about 45% of Alumis’ shares — which currently trade around $5 apiece — in the planned merger. Acelyrin said its board will act in “the best interests of all stockholders” and it will make a further announcement “in due course.” If approved by shareholders, its merger with Alumis would close in the second quarter. — Ben Fidler
Intra-Cellular Therapies, maker of the mind-stabilizing medicine Caplyta, reported on Friday that net sales of the product totaled almost $681 million last year. That sum is up 47% compared to 2023. Caplyta is already approved in the U.S. as a treatment for schizophrenia and bipolar depression, and could be cleared in major depression before too long. Sensing the drug’s blockbuster potential, Johnson & Johnson recently agreed to acquire Intra-Cellular for nearly $15 billion. The deal is expected to close later this year. — Jacob Bell